A genome-based strategy uncovers frequent BRAF mutations in melanoma.
about
Rewired ERK-JNK signaling pathways in melanomaSynergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor RapamycinChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Updates in Therapy for Advanced MelanomaNRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.Systemic Therapies for Late-stage MelanomaParthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathwayLatest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.Macrophage inhibitory cytokine-1 regulates melanoma vascular developmentA chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translationPhospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancerSuperficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail.Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis.Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosisGlobal comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenografts.Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation.Molecular classification and biomarker discovery in papillary thyroid carcinoma.Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylationAbsence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.Metastatic melanoma - a review of current and future drugsHuman cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.PAX3 across the spectrum: from melanoblast to melanoma.Genetics of uveal melanoma and cutaneous melanoma: two of a kind?Towards new therapeutic approaches for malignant melanoma.Controversial aspects of oncogene-induced senescence.A Wnt-er migration: the confusing role of β-catenin in melanoma metastasis.BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.The roles of microphthalmia-associated transcription factor and pigmentation in melanoma.A-Raf: A new star of the family of raf kinases.CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.Structural optimization and biological screening of a steroidal scaffold possessing cucurbitacin-like functionalities as B-Raf inhibitors.Mouse models of UV-induced melanoma: genetics, pathology, and clinical relevance.Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma.Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatmentCharacterization of Ser338 phosphorylation for Raf-1 activationActivating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
P2860
Q24683737-9D511E06-361A-4611-BDC4-55AA5297E0C4Q24811525-2C099BEA-B07D-40B5-A16D-2961178AAD11Q26770492-17365B59-4B6A-4B61-80E5-ABF64483A72DQ26771119-51258609-61D9-48EC-848E-14BA2DD5E90BQ27852445-32B49A05-4267-4CDE-8B1C-A678EA7ED42AQ28080215-8CF883F0-AF3F-42D5-AD12-98E0D618CDD6Q33618711-3A066E3A-0412-4473-8C65-9F732FAEF54BQ33667485-5150B4B0-5176-4287-B97F-4A47221DCF19Q33882542-4720E7C6-3FA1-4EFF-AFB5-951FB84D86C5Q33934987-2239E371-E6E4-46D6-8D94-5F188B213DF0Q34268347-71A68D32-CB2D-486D-B3D4-5B594E2A9A12Q34633885-77715B2A-D14F-4C4F-AD14-403403D00747Q34838275-7ADD64D5-BEC4-4136-A9CD-2B8D96E2D677Q35132940-5E5426E4-F824-490B-A44C-8CD89C49DC72Q35147986-0CEBA6C3-387F-458A-BD18-2065A761CC1FQ35580942-F352DF80-7A74-4120-A7F7-7B4387367953Q35581006-254156C9-BA96-4C6D-8C9A-537C67F7EA19Q35635353-518A9AD3-025B-47D1-B4AA-B42903E9A939Q35779541-33F72A4B-59CF-45AD-97DD-6F7F70FD3259Q36299916-A2C9C3EF-4BCD-49EB-BDE7-EDF347E389F6Q36562077-D8224176-80CF-4C35-8737-E8CB86117F4FQ36685109-DA747F85-6759-4674-A017-EB90BBB30A0DQ37340405-B0E3E837-EAA4-4BFB-900E-DE0DD2491CEDQ37450733-F0D34342-CAE1-4E72-8282-D9DC98635738Q37453821-B68A5597-A59A-4BFB-9035-B1655EA6A001Q37463808-3EDCEADF-16A6-4041-95F0-B6EBEE9A4DF0Q37772777-9BA63DAD-F0F5-4CE8-A585-E16CB7930BAEQ37951743-B8827452-E136-464E-88C9-F826CF3C1DA1Q38055308-05189C94-8DCA-43A2-A14A-DC0FBD254408Q38093429-D5A59439-63CE-4E86-9D2A-8B51349C0411Q38176858-43A8326F-43BE-497B-ABD0-C7C82C543038Q38238861-5BF9C7FE-574F-49E8-A505-7D5014D4ACBCQ38618036-2E748D80-1BAE-4F1B-819D-D6A1F42C504DQ38900723-D15FD386-C847-4B82-8948-386BDCECCFAAQ39010090-0C9ABF35-4DB2-496B-AF9A-30421BC5D2F9Q39090543-887992BC-06C6-4DC5-93FC-7FBE5F121883Q39201632-F380D395-C603-415E-A457-7C704A54B1EDQ39661214-CC2BA3D4-DA44-4662-A5D7-C18153BEB5E2Q39942488-0ECE9EDB-127F-498E-A669-EEC0A0BE0D78Q40606325-CECD3707-3B69-48D2-A433-63224CE92E35
P2860
A genome-based strategy uncovers frequent BRAF mutations in melanoma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
A genome-based strategy uncovers frequent BRAF mutations in melanoma.
@en
A genome-based strategy uncovers frequent BRAF mutations in melanoma.
@nl
type
label
A genome-based strategy uncovers frequent BRAF mutations in melanoma.
@en
A genome-based strategy uncovers frequent BRAF mutations in melanoma.
@nl
prefLabel
A genome-based strategy uncovers frequent BRAF mutations in melanoma.
@en
A genome-based strategy uncovers frequent BRAF mutations in melanoma.
@nl
P1433
P1476
A genome-based strategy uncovers frequent BRAF mutations in melanoma.
@en
P2093
Paul S Meltzer
P356
10.1016/S1535-6108(02)00089-2
P577
2002-07-01T00:00:00Z